Imunon annual operating expenses
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Imunon Operating Expenses Growth & History (IMNN)
Imunon's operating expenses was $14.7M for fiscal 2025.
View full Imunon company overviewImunon annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $14.7M | −$4.5M | −23.42% |
| 2024 | 2024-12-31 | $19.1M | −$1.9M | −9.02% |
| 2023 | 2023-12-31 | $21.0M | −$4.4M | −17.27% |
| 2022 | 2022-12-31 | $25.4M | $3.9M | +18.20% |
| 2021 | 2021-12-31 | $21.5M | $2.5M | +13.28% |
| 2020 | 2020-12-31 | $19.0M | −$2.1M | −9.87% |
| 2019 | 2019-12-31 | $21.1M | −$499,571 | −2.32% |
| 2018 | 2018-12-31 | $21.6M | $2.6M | +13.69% |
| 2017 | 2017-12-31 | $19.0M | −$2.2M | −10.31% |
| 2016 | 2016-12-31 | $21.1M | −$196,973 | −0.92% |
| 2015 | 2015-12-31 | $21.3M | −$3.9M | −15.34% |
| 2014 | 2014-12-31 | $25.2M | $9.3M | +58.47% |
| 2013 | 2013-12-31 | $15.9M | −$6.2M | −28.14% |
| 2012 | 2012-12-31 | $22.1M | −$2.9M | −11.50% |
| 2011 | 2011-12-31 | $25.0M | $5.4M | +27.40% |
| 2010 | 2010-12-31 | $19.6M | — | — |
Imunon quarterly operating expenses
Q2.10
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.8M | $23,682 | +0.86% |
| Q1 2026 | 2026-03-31 | $4.3M | $161,253 | +3.89% |
| Q4 2025 | 2025-12-31 | $4.3M | $115,521 | +2.79% |
| Q3 2025 | 2025-09-30 | $3.5M | −$1.5M | −29.94% |
| Q2 2025 | 2025-06-30 | $2.8M | −$2.2M | −44.79% |
| Q1 2025 | 2025-03-31 | $4.1M | −$866,147 | −17.28% |
| Q4 2024 | 2024-12-31 | $4.1M | −$1.8M | −30.52% |
| Q3 2024 | 2024-09-30 | $5.0M | $1.1M | +27.08% |
| Q2 2024 | 2024-06-30 | $5.0M | −$460,934 | −8.42% |
| Q1 2024 | 2024-03-31 | $5.0M | −$673,004 | −11.84% |
| Q4 2023 | 2023-12-31 | $6.0M | −$1.1M | −15.37% |
| Q3 2023 | 2023-09-30 | $3.9M | −$2.4M | −38.03% |
| Q2 2023 | 2023-06-30 | $5.5M | −$628,986 | −10.31% |
| Q1 2023 | 2023-03-31 | $5.7M | −$282,527 | −4.73% |
| Q4 2022 | 2022-12-31 | $7.1M | $1.4M | +25.57% |
| Q3 2022 | 2022-09-30 | $6.3M | $1.1M | +21.46% |
| Q2 2022 | 2022-06-30 | $6.1M | $906,869 | +17.45% |
| Q1 2022 | 2022-03-31 | $6.0M | $458,633 | +8.33% |
| Q4 2021 | 2021-12-31 | $5.6M | $697,048 | +14.17% |
| Q3 2021 | 2021-09-30 | $5.2M | $901,976 | +21.05% |
| Q2 2021 | 2021-06-30 | $5.2M | $304,405 | +6.22% |
| Q1 2021 | 2021-03-31 | $5.5M | $617,349 | +12.62% |
| Q4 2020 | 2020-12-31 | $4.9M | $46,154 | +0.95% |
| Q3 2020 | 2020-09-30 | $4.3M | −$1.2M | −22.28% |
| Q2 2020 | 2020-06-30 | $4.9M | −$802,761 | −14.10% |
| Q1 2020 | 2020-03-31 | $4.9M | −$94,528 | −1.90% |
| Q4 2019 | 2019-12-31 | $4.9M | −$2,701 | −0.06% |
| Q3 2019 | 2019-09-30 | $5.5M | $1.4M | +32.92% |
| Q2 2019 | 2019-06-30 | $5.7M | −$2.4M | −30.01% |
| Q1 2019 | 2019-03-31 | $5.0M | $579,419 | +13.15% |
| Q4 2018 | 2018-12-31 | $4.9M | −$103,473 | −2.08% |
| Q3 2018 | 2018-09-30 | $4.1M | −$375,877 | −8.31% |
| Q2 2018 | 2018-06-30 | $8.1M | $3.6M | +79.88% |
| Q1 2018 | 2018-03-31 | $4.4M | −$537,294 | −10.87% |
| Q4 2017 | 2017-12-31 | $5.0M | −$280,004 | −5.32% |
| Q3 2017 | 2017-09-30 | $4.5M | −$1.2M | −20.95% |
| Q2 2017 | 2017-06-30 | $4.5M | −$342,580 | −7.04% |
| Q1 2017 | 2017-03-31 | $4.9M | −$360,298 | −6.79% |
| Q4 2016 | 2016-12-31 | $5.3M | $186,955 | +3.69% |
| Q3 2016 | 2016-09-30 | $5.7M | $1.4M | +31.02% |
| Q2 2016 | 2016-06-30 | $4.9M | −$503,865 | −9.38% |
| Q1 2016 | 2016-03-31 | $5.3M | −$1.2M | −18.88% |
| Q4 2015 | 2015-12-31 | $5.1M | −$1.5M | −22.64% |
| Q3 2015 | 2015-09-30 | $4.4M | −$2.4M | −35.72% |
| Q2 2015 | 2015-06-30 | $5.4M | −$1.2M | −17.87% |
| Q1 2015 | 2015-03-31 | $6.5M | $1.2M | +22.74% |
| Q4 2014 | 2014-12-31 | $6.6M | $3.2M | +93.55% |
| Q3 2014 | 2014-09-30 | $6.8M | $3.1M | +85.69% |
| Q2 2014 | 2014-06-30 | $6.5M | $2.6M | +64.55% |
| Q1 2014 | 2014-03-31 | $5.3M | $435,119 | +8.89% |
| Q4 2013 | 2013-12-31 | $3.4M | −$1.8M | −35.01% |
| Q3 2013 | 2013-09-30 | $3.7M | −$1.3M | −26.23% |
| Q2 2013 | 2013-06-30 | $4.0M | −$1.7M | −30.38% |
| Q1 2013 | 2013-03-31 | $4.9M | −$1.4M | −21.90% |
| Q4 2012 | 2012-12-31 | $5.2M | −$1.2M | −18.38% |
| Q3 2012 | 2012-09-30 | $5.0M | −$1.9M | −27.31% |
| Q2 2012 | 2012-06-30 | $5.7M | −$538,482 | −8.62% |
| Q1 2012 | 2012-03-31 | $6.3M | $699,554 | +12.57% |
| Q4 2011 | 2011-12-31 | $6.4M | — | — |
| Q3 2011 | 2011-09-30 | $6.8M | $1.7M | +31.94% |
| Q2 2011 | 2011-06-30 | $6.2M | $1.8M | +39.90% |
| Q1 2011 | 2011-03-31 | $5.6M | — | — |
| Q3 2010 | 2010-09-30 | $5.2M | — | — |
| Q2 2010 | 2010-06-30 | $4.5M | — | — |
Imunon operating expenses trends
Over the last five fiscal years, Imunon's operating expenses decreased from $19.0M to $14.7M, a change of −$4.3M. The latest reported quarter, Q2 2026, shows $2.8M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Imunon source filings ↗Community posts
IMUNON signs an NCI agreement to expand development of IMNN-001
IMUNON ($IMNN) entered a Cooperative Research and Development Agreement with the US National Cancer Institute for IMNN-001, its DNA-based IL-12 immunotherapy. NCI’s Cancer Therapy Evaluation Program will assume regulatory sponsorship and su ...